The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study
Wei Jin,1,* Jian-Chun Duan,2,* Zhi-Jie Wang,2 Lin Lin,2 Hua Bai,2 Jie Wang,2 Li Feng1 1Department of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, People&...
Main Authors: | Jin W, Duan JC, Wang ZJ, Lin L, Bai H, Wang J, Feng L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-11-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-effect-and-safety-of-anti-pd-1-singlecombination-therapy-in-refrac-peer-reviewed-article-CMAR |
Similar Items
-
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression
by: Takuma Isshiki, et al.
Published: (2018-10-01) -
Clinical Analysis of 45 Patients with Thymic Carcinoma
by: Ruitai FAN, et al.
Published: (2009-04-01) -
Thymoma and thymic carcinoma associated with multilocular thymic cyst: a clinicopathologic analysis of 18 cases
by: Xuxia Shen, et al.
Published: (2018-06-01) -
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
by: Isabelle Rouquette, et al.
Published: (2019-12-01) -
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
by: Kyoichi Kaira, et al.
Published: (2021-03-01)